A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC).

Trial Profile

A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Temsirolimus (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
    • 25 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 25 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top